“The Opioid Crisis: Justice and Accountability” Virtual Event


June 8, 2020


The Opioid Crisis: Justice and Accountability

A Virtual Event in Partnership with the Financial Times 

Tuesday, June 23rd at 8:00pm EST

Please join us ahead of the broadcast premiere of Opioids, Inc. for a virtual discussion about holding big pharmaceutical companies accountable with the film’s director, Tom Jennings, and the US Pharma and Biotech correspondent for the Financial Times, Hannah Kuchler. 

8-9PM EST: Virtual Discussion with audience Q&A

10pm EST: Broadcast Premiere of Opioids, Inc. on FRONTLINE PBS (check local listings) 

In Opioids Inc., FRONTLINE PBS and the Financial Times teamed up to co-investigate the corrupt practices behind the rise of the pharmaceutical company Insys Therapeutics, as they bribed doctors to prescribe a highly addictive opioid painkiller that is 50 to 100 times stronger than heroin.

The virtual discussion will preview clips from the film and feature a deep dive into the problematic marketing tactics of the pharmaceutical industry and why prosecutors pursued Insys Therapeutics using statutes originally designed for the mafia. 



Hannah Kuchler: US Pharma and Biotech Correspondent, the Financial Times 

Tom Jennings: Film Director/Producer of Opioids Inc., FRONTLINE PBS

Shaunagh Connaire: US Editor of Alpha Grid, the Financial Times

Moderated by Lauren Ezell: Senior Editor, FRONTLINE PBS


This is a free virtual event that will be hosted on Zoom. You must RSVP in order to receive the Zoom link, which will be included in your email confirmation. If you are new to Zoom, please visit this Quick start guide for new users

In order to foster a civil and literate discussion that respects all participants, FRONTLINE has the following guidelines for commentary. By submitting comments here, you are consenting to these rules:

Readers' comments that include profanity, obscenity, personal attacks, harassment, or are defamatory, sexist, racist, violate a third party's right to privacy, or are otherwise inappropriate, will be removed. Entries that are unsigned or are "signed" by someone other than the actual author will be removed. We reserve the right to not post comments that are more than 400 words. We will take steps to block users who repeatedly violate our commenting rules, terms of use, or privacy policies. You are fully responsible for your comments.

blog comments powered by Disqus